Arvinas Stock Price, News & Analysis

Arvinas (NASDAQ: ARVN) will present new preclinical data for ARV-393, their investigational oral PROTAC BCL6 degrader, at the European Hematology Association (EHA) meeting in Milan, Italy from June 12-15, 2025. ARV-393 targets the B-cell lymphoma 6 protein (BCL6), a key driver of B-cell lymphomas. The presentation will showcase preclinical studies of ARV-393 as both a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in diffuse large B-cell lymphoma models. The poster presentation is scheduled for June 13, 2025, from 6:30-7:30 p.m. CEST.

Arvinas and Pfizer announced significant Phase 3 VERITAC-2 trial results for vepdegestrant, their novel PROTAC drug for advanced breast cancer. The drug showed a 2.9-month improvement in median progression-free survival compared to fulvestrant in ESR1-mutant, ER+/HER2- breast cancer patients, reducing disease progression risk by 43%. Vepdegestrant demonstrated strong efficacy with a median PFS of 5.0 months versus 2.1 months for fulvestrant in ESR1-mutant patients. The drug was well-tolerated with low rates of gastrointestinal side effects and few discontinuations. As the first PROTAC evaluated in Phase 3 trials showing benefit in breast cancer patients, Arvinas and Pfizer plan to submit an NDA to the FDA in H2 2025. The trial results were presented at ASCO and published in the New England Journal of Medicine.

Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation drug development, announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat on June 5, 2025, at 2:35 p.m. ET in New York City. Investors and interested parties can access a live audio webcast of the presentation through the company's website under the "Events and Presentations" section of the Investors and Media page.

Arvinas (ARVN) reported Q1 2025 financial results and significant corporate updates. The company announced positive Phase 3 VERITAC-2 trial results for vepdegestrant in breast cancer, supporting upcoming regulatory filings. However, Arvinas and Pfizer removed two planned Phase 3 combination trials from their development plan. The company presented promising first-in-human data for ARV-102 in neuroscience, showing effective blood-brain barrier penetration. Financially, Arvinas reported $954.3 million in cash and $188.8 million in revenue for Q1 2025. The company announced a significant restructuring, including a workforce reduction of approximately one-third, to extend cash runway into H2 2028. R&D expenses were $90.8 million, up from $84.3 million year-over-year, while G&A expenses increased to $26.6 million from $24.3 million.

Arvinas (NASDAQ: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025, at 8:00 a.m. ET. The company will host a live webcast accessible through the 'Events and Presentations' section of their investor relations webpage. A recording of the webcast will be made available on www.arvinas.com after the event.

Arvinas (NASDAQ: ARVN) presented promising preclinical combination data for ARV-393, their PROTAC BCL6 degrader, at the 2025 AACR Annual Meeting. The study demonstrated significant antitumor activity in non-Hodgkin lymphoma models.

Key findings showed that ARV-393 combined with standard-of-care R-CHOP chemotherapy achieved complete tumor regressions in all treated mice. The drug also showed strong synergy when combined with biologics targeting CD20, CD19, or CD79b, and with small molecule inhibitors targeting BTK, BCL2, or EZH2.

Notably, ARV-393 increased CD20 expression, supporting its potential use with CD20-targeted therapies. A Phase 1 study (NCT06393738) is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL.

Arvinas (NASDAQ: ARVN) announced that results from its Phase 3 VERITAC-2 clinical trial will be presented as a late-breaking oral presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will reveal the first pivotal data for vepdegestrant, a potential first-in-class oral PROTAC estrogen receptor degrader, being developed jointly with Pfizer.

The trial evaluated vepdegestrant versus fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The presentation, scheduled for May 31, 2025, will be delivered by Dr. Erika P. Hamilton from the Sarah Cannon Research Institute's Breast Cancer Research Program.

Arvinas (NASDAQ: ARVN) announced it will present new preclinical combination data for ARV-393, their investigational PROTAC BCL6 degrader, at the upcoming AACR Annual Meeting in Chicago (April 25-30, 2025). The presentation will focus on ARV-393's potential combination with standard lymphoma treatments.

The research highlights ARV-393, a PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), which is a transcriptional repressor and major driver of B-cell lymphomas. The poster presentation, titled 'ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models,' will be presented on April 28, 2025.

Arvinas (ARVN) presented promising first-in-human clinical trial data for ARV-102, their investigational oral PROTAC LRRK2 degrader, at AD/PD™ 2025. The trial demonstrated that ARV-102 successfully penetrates the blood-brain barrier and achieves substantial LRRK2 protein degradation in both central and peripheral systems.

Key findings showed ARV-102 was well-tolerated with no serious adverse events. At single doses ≥60mg and daily doses ≥20mg, the drug achieved >50% LRRK2 reduction in cerebrospinal fluid and >90% reduction in peripheral blood mononuclear cells. The Phase 1 trial included single ascending dose (SAD) cohorts (10-200mg) and multiple ascending dose (MAD) cohorts (10-80mg).

The company has initiated a Phase 1 trial in Parkinson's disease patients and expects to complete enrollment and present initial data from the SAD cohort, as well as initiate the MAD cohort, in 2025.